Biotechnology

Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) jumped 44.5% to close at $1.20. NeuroOne, last month, received...

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo...

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at $3.21 on Friday. Piper Sandler cut the price target for Heska Corporation (NASDAQ: HSKA) from $...

Moleculin Biotech Inc (NASDAQ: MBRX) announced that its WP1096 molecule would be evaluated in animal studies by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.  Moleculin studies WP1096 as a novel potential therapy...

Luna Innovations Inc (NASDAQ: LUNA) announced a new $14.2 million contract with its long-standing partner Intuitive Surgical Inc (NASDAQ: ISRG). This new agreement provides for the supply of critical photonic subsystems manufactured by Luna and incorporated into Intuitive...

Neurocrine Biosciences Inc (NASDAQ: NBIX) has agreed to pay £48.3 million for the U.K. hormone therapy group, Diurnal Group Plc. The 27.5p share offered represents a 141% premium to last Friday's closing price. "Diurnal and Neurocrine are highly complementary...

Janssen Biotech Inc, a Johnson & Johnson (NYSE: JNJ) unit, received European conditional approval for Tecvayli (teclistamab) as monotherapy for relapsed or refractory multiple myeloma.  Teclistamab is a T-cell redirecting bispecific antibody targeting both B-cell...

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients....

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults. Axsome shares traded in a range of $50.5 to $61...

Tucked in its Q2 earning release, Neurocrine Biosciences Inc (NASDAQ: NBIX) said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints.  Based on the totality of data from the Phase 2a study, at this time, the company will not proceed...

U.S. gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider...

Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading. ThermoGenesis Holdings, Inc. (NASDAQ: THMO) rose 34.3% to $0.2850 in pre-market trading after gaining over 6% on Thursday. ECB Bancorp, Inc. (NASDAQ: ECBK) rose 34.1% to $18.90 in pre-market trading after...

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022. SKYX Platforms Corp. (NASDAQ: SKYX) gained 68.6% to settle at $7.03. Benchmark initiated...

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 231% to $2.63 on news that the company will be acquired By Henry Crown and Company for $3.25 per share. Petros Pharmaceuticals, however, confirmed that a press release regarding a purported acquisition of the company was fraudulent and not...

Gainers JAKKS Pacific, Inc. (NASDAQ: JAKK) rose 34.7% to $23.01 in pre-market trading after the company reported better-than-expected Q2 results. Athersys, Inc. (NASDAQ: ATHX) rose 35.1% to $0.2568 in pre-market trading after gaining 10% on Wednesday. Athersys is expected to release its Q2...